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Abstract
Background: The results of treatment for malignant bone and soft-tissue tumors arising from the deep trunk and
pelvis are still not acceptable due to the relatively high recurrence and low overall survival rates. Recently, carbon
ion radiotherapy (CIRT) was applied for several malignancies, including bone and soft-tissue sarcomas, and provided
favorable results. However, it has been unclear what modalities should be used for evaluating the response and for
the follow-up of these patients. Here, we analyzed the methods used to predict local recurrence and to find local
failures or metastases.
Methods: We analyzed 37 patients with bone and soft-tissue tumors who received CIRT at our institute. The patients
were examined with FDG positron emission tomography (PET) and enhanced MRI before and three months after CIRT.
The pre-treatment maximum standardized uptake value (SUVmax), and that three months after treatment, the
difference between the pre- and post-CIRT SUVmax, the ratio of the post- to pre-SUVmax in FDG-PET and the size
of the tumors were evaluated as predictors for local recurrence. FDG-PET and enhanced MRI were used to detect
local recurrence.
Results: Local recurrence appeared in 10 cases after CIRT. Nine of the 10 lesions (90.0 %) were detected with
FDG-PET, while enhanced MRI detected just 50.0 % of the recurrences. One case of local recurrence, in which the
lesion was negative on FDG-PET, was detected using enhanced MRI. A receiver operating characteristic curve
analysis showed that neither the SUVmax on FDG-PET nor the tumor size before or three months after CIRT could
be used to predict local recurrence.
Conclusions: The combination of FDG-PET and enhanced MRI is recommended to detect local recurrence for
patients with sarcomas who have received CIRT; however, no parameters obtained during the examinations
performed before and three months after CIRT accurately predicted the development of local recurrence.
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Background
Treatment of malignant bone and soft-tissue tumors
arising from the deep trunk and pelvis is usually difficult
because of their anatomical characteristics and relatively
huge size due to a delayed diagnosis. Tumors located in
the trunk or pelvis are known to carry a risk for local re-
currence after surgical resection in patients with malig-
nant soft-tissue tumors [1, 2], and the overall survival
rate and local control rate of osteosarcoma in the trunk
and pelvis were inferior to those of the extremities [3–5].
Our institute started performing carbon ion radiotherapy
(CIRT) in 2010, and has treated various kinds of tumors,
including sarcomas originating from the trunk and pelvis,
for which surgical treatment is difficult or impossible [6].
The carbon ion beam exhibits a higher linear energy trans-
fer to the target lesions than does a photon beam, resulting
in the induction of effective damage to tumor cells [7].
Recently, CIRT was reported to achieve favorable results
for the treatment of malignant bone and soft-tissue sarco-
mas located around the trunk and pelvis, especially for
chordoma [8–10].
However, there remain issues associated with the use
of CIRT, one of which is how to evaluate the tumor re-
sponse just after treatment. Due to the lacking of surgical
specimens, a pathological evaluation is impossible in the
inoperable cases treated with CIRT. Performing a needle
biopsy after CIRT may partially resolve this problem; how-
ever, the small amount of samples collected during such
biopsies is associated with a risk of overlooking recur-
rence. Therefore, modalities that can precisely evaluate
the tumor response after CIRT are required.
One candidate modality is 2-deoxy-2-[F-18] fluoro-D-
glucose positron emission tomography (FDG-PET), which
has been used to evaluate the response of sarcomas to neo-
adjuvant chemotherapy. The FDG accumulation, presented
as the standardized uptake value (SUV), after treatment or
the ratio of the post- to pre-treatment SUV were reported
to correlate with the proportion of tumor necrosis [11]. Evi-
levitch et al. showed that a reduction of FDG uptake more
accurately predicted the histopathological response of high-
grade soft-tissue sarcomas to neoadjuvant chemotherapy
than did a change in tumor size [12].
The purpose of this study was to analyze the modal-
ities used to evaluate the effects of CIRT on bone and
soft-tissue sarcomas and identify the best method for




The patients who had bone and soft-tissue tumors in the
trunk, and whose tumors were unresectable or difficult
to surgically treat without causing severe dysfunction
were eligible for CIRT. We reviewed 55 patients with
bone and soft-tissue tumors who were treated with CIRT
at our institute from November 2010 to January 2014,
and who were followed-up for at least one year. Among
them, 13 patients were excluded because they did not
receive pre- or post-treatment FDG-PET/CT, three pa-
tients were excluded because chemotherapy was started
within 1 month after CIRT, and this factor might affect
the SUV of FDG-PET, and two patients who were treated
with postoperative CIRT were excluded because their tu-
mors were not radiologically detected prior to treatment.
The remaining 37 patients were analyzed in this study. The
patients were examined with FDG-PET/CT and enhanced
MRI before and three months after CIRT. After that, exam-
inations were performed at three to six month intervals to
screen for metastases and recurrences. Screening for distant
metastases was performed using FDG-PET/CT because of
its usefulness in detecting musculoskeletal metastases [13].
The regions treated with CIRT were the sacrum in 10
patients, intrapelvic region in six, retroperitoneum in
four, acetabulum in three, cervical spine in three, and
other locations in the other patients.
Institutional Review Board approval was obtained on
April 28, 2010 with registration number 765. Written in-
formed consent was obtained from all subjects (patients)
in this study.
CIRT
The details of the CIRT technique and the modalities
used at the Gunma University Heavy Ion Medical Center
(GHMC) have been reported previously [6]. Briefly, the
carbon ion beams generated by the GHMC had maximum
accelerated energies of 400 million electron volts per nu-
cleon (MeV/n). The planning target volume included the
clinical target volume plus a 5 mm safety margin. The
dose was expressed as the Gy (RBE) (the carbon physical
dose [Gy] x relative biologic effectiveness [RBE]). The
treatment was performed once a day at doses ranging
from 64.0 to 70.4 Gy (RBE) for a total of 16 fixed fractions.
The patients who received pre-CIRT chemotherapy re-
ceived CIRT at least four weeks after the last dose of
chemotherapy.
FDG-PET/CT
The patients fasted for 6 h before the intravenous injec-
tion of 18F-FDG (5 MBq/kg). FDG PET/CT images were
acquired 1 h after injection with the Discovery STE
PET/CT scanner (GE Healthcare, Milwaukee WI) and
Biograph 16 PET/CT scanner (Siemens, Malvem, PA).
All PET images were independently interpreted by two
experienced doctors of nuclear medicine. Functional images
of the SUV were produced for a semiquantitative analysis.
The SUV was defined as follows: SUV= radioactive con-
centration in the region of interest (MBq/g)/injected dose
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(MBq)/patient’s body weight (g). The SUVmax was defined
as the peak SUV within the region of interest.
Evaluation of predictors of interest
Several values have previously been utilized for predict-
ing the effects of chemotherapy on bone and soft-tissue
sarcomas. According to previous reports, the pre-treatment
SUVmax (pre-Tx SUVmax), that three months after treat-
ment (post-Tx SUVmax), the difference between the
pre- and post-Tx SUVmax (ΔSUVmax) and the ratio of
the post-Tx SUVmax to pre-Tx SUVmax (ratio of SUV-
max) in FDG-PET/CT were evaluated as predictors. In
addition, the maximum dimension of the pre-and post-
treatment tumors were also evaluated. The pre-treatment
tumor size (pre-Tx tumor size), post-treatment tumor size
(post-Tx tumor size), difference in tumor size between the
pre- and post-Tx measurements (Δtumor size) and the ra-
tio of the post-Tx tumor size to the pre-Tx size (ratio of
tumor size) were defined as parameters. The tumor size
was measured with MRI, and the response to the treat-
ment was classified into four groups: complete response,
partial response, progressive disease and stable disease ac-
cording to the RECIST version 1.1 [14]. We regarded local
recurrence as an indicator of the effects of CIRT in the
current study, because unlike an evaluation of neoadjuvant
chemotherapy, a pathological analysis could not be used
to evaluate the effects of the CIRT on the tumors. The
findings regarding local recurrence were an increase or
emergence of FDG accumulation in FDG-PET/CT and a
gadolinium-enhanced lesion on MRI without indications
for inflammatory diseases, such as an infection.
Statistical analysis
The sensitivity and specificity for the prediction of local
recurrence by each predictor of interest were calculated,
and receiver operating characteristic (ROC) curves were
created. Using the ROC curves, the propensity of the
predictors to predict local recurrence was compared to
that of the reference, which had an area under the curve
(AUC) of 0.5. The cut-off point that minimized the distance
between the point (0, 1) on the upper left hand corner of
the ROC space and ROC curve was defined as optimal.
The sample size was based on a significance level of 5 %, a
power level of 80 %, an expected AUC = 0.8 and a 25 %
recurrence rate after CIRT, which was estimated from
previous reports [8, 15]. The required sample size was
36. The differences in the values of the predictors between
the recurrence and no recurrence groups were analyzed
with t-tests. The difference between the pre-and post-Tx
SUVmax by FDG-PET/CT and the pre- and post-Tx
tumor sizes were analyzed with paired t-tests. The statis-
tical analyses for sample size estimation were performed
using the MedCalc Statistical Software program, version
13.3.3 (MedCalc Software bvba, Ostend, Belgium; http://
www.medcalc.org; 2014), and the others were performed
with the SPSS software program (version 22.0; IBM Cor-
poration, Somers, NY).
Results
Characteristics of the patients
The patients comprised 25 males and 12 females, and the
mean age at CIRT was 62.9 years (range: 34 to 84 years).
The mean follow-up period after CIRT was 25.9 months
(range: 12 to 49 months). The pathological diagnoses are
presented in Table 1. One patient with dedifferentiated
liposarcoma underwent palliative chemotherapy more
than one month after CIRT. Three patients died of the
disease and one died of another disease. All patients could
receive FDG-PET/CT before CIRT and three months after
CIRT, while two patients could not be examined with en-
hanced MRI because one had wires in the sternum near
the lesions and one missed the examination three months
after CIRT.
Local recurrence and metastasis
Local recurrence appeared in 10 cases (27.0 %) after CIRT,
with a mean duration of 13.9 (range: 5–25) months from
treatment to relapse. Nine of the 10 lesions (90.0 %) were
detected with FDG-PET/CT. Enhanced MRI was per-
formed for 8 of the 10 cases, which detected 4 local recur-
rences (50.0 %). FDG-PET/CT found four local recurrences
that enhanced MRI could not, while enhanced MRI could
detect only one lesion that FDG-PET/CT missed (Fig. 1).
Figure 2 shows the case with dedifferentiated chondrosar-
coma, in which FDG-PET/CT could detect local recurrence
after CIRT, although enhanced MRI could not. FDG-PET/
CT and whole body CT detected distant metastasis in
two cases.
Evaluation of the predictors of local recurrence
There were no significant differences between the pre-
and post-Tx tumor size (83.3 [16–180] mm vs 81.6





desmoid type fibromatosis 2
myxofibrosarcoma 2
malignant peripheral nerve sheath tumor 2
rhabdomyosarcoma 1
malignant solitary fibrous tumor 1
sclerosing epithelioid fibrosarcoma 1
well-differentiated liposarcoma 1
total 37
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[15–172] mm, p = 0.29). All cases were classified to
have stable disease. However, the SUVmax was signifi-
cantly reduced three months after CIRT (Table 2). The
differences in the values of the predictors for local re-
currence between the recurrence and no recurrence
groups are summarized in Table 3. Only the post-Tx
SUVmax showed a significantly higher value in the recur-
rence group than in the no recurrence group. Among the
examined predictors, there were no factors that were
significantly superior for predicting local recurrence after
Fig. 1 An undifferentiated sarcoma occurred in the chest wall of a 74-year-old male. A small enhanced lesion persisted three months after CIRT
(a), and the size of the lesion increased on MRI performed five months after CIRT (b). FDG-PET/CT showed no change in the FDG accumulation
between before (c) and after the recurrence (d)
Fig. 2 A recurrent tumor in a 79-year-old male with dedifferentiated chondrosarcoma. There were no mass lesions detected by enhanced MRI before
(a) or after (b) the metastasis. CIRT induced a remission of the FDG accumulation noted by FDG-PET/CT three months after CIRT (c); however, a new
lesion with high SUV appeared five months after CIRT (d)
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CIRT (Table 4). Even the post-Tx SUVmax, which had the
largest AUC of the various predictors examined, showed
an insufficient sensitivity (70.0 %) and specificity (77.8 %),
with an optimum cut-off value of 3.80.
Discussion
The current study showed that CIRT performed at our
institute could treat inoperable bone and soft-tissue tu-
mors with an acceptable recurrence rate as low as that
in previous reports [8–10]. CIRT induced a significant
decrease of FDG accumulation in the target tumors, and
the post-Tx SUVmax in the recurrence group was sig-
nificantly higher than that in the no recurrence group.
These results suggested that CIRT could downregulate
the tumor metabolism, and the tumors that exhibited
decreased glucose transport activity following CIRT
showed a reduced risk of local recurrence. Meanwhile,
the tumor size was hardly changed after CIRT, and
seemed to be inappropriate for evaluating the response
to the treatment, which was consistent with previous re-
ports showing that the SUV from FDG-PET/CT was su-
perior to changes in tumor size for predicting tumor
necrosis induced by neoadjuvant chemotherapy [12].
While a favorable effect of CIRT to reduce the tumor
activity was shown, the present study also showed that
accurately predicting the local recurrence of sarcomas
after CIRT was difficult even when using the SUV to
indicate the tumor metabolic activity. The presence of
patients who had a relapse in spite of a decrease of the
SUVmax in their lesions, and those who experienced
no recurrence who did not show a change in their
SUVmax after CIRT led to a low accuracy for predict-
ing local recurrence with FDG-PET/CT. The probable
reasons for the discrepancy between local recurrence
and the tumor metabolism in some cases were as fol-
low: First, most of the target tumors were composed of
heterogeneous populations of cells. All of the recurrent
tumors were detected as a much smaller lesion than
the original tumors, which meant that a small popula-
tion resistant to CIRT likely developed and appeared in
PET and MRI as a recurrence, while most of the
remaining original tumor was killed by CIRT. Second,
there was a possibility that not only surviving tumor
cells, but also remaining inflammatory cells in the
treated lesion contributed to FDG accumulation. Previ-
ous reports speculated that inflammatory reactions
evoked by radiation would increase the FDG uptake,
and recommended that PET be performed more than
six months and 12 weeks after radiotherapy to effectively
detect residual colorectal tumors and non-small-cell lung
cancers, respectively [16, 17]. In the current study, the
earliest local recurrence occurred at five months after
CIRT; and therefore, the prediction of the relapse would
need to be performed earlier than that.
In clinical practice, early detection of the treatment re-
sponse is important when providing follow-up for pa-
tients with malignant tumors, as the use of salvage and/
or adjuvant treatment, even if relatively risky, should be
considered as soon as possible if the risk of recurrence is
high. However, the administration of additional therapy
based on the findings of examinations with low specifi-
city for detecting recurrence may worsen the patient’s
status and quality of life without providing any major
benefits.
Currently, there are no reliable modalities that can
accurately predict the development of local recurrence
Table 2 Difference in SUVmax and tumor size between
pre- and post-CIRT
pre-CIRT post-CIRT p-value
SUVmax 4.92 ± 3.68a 3.30 ± 2.08 <0.01
tumor size (mm) 83.27 ± 35.27 81.62 ± 35.97 0.29
*significant p-value was bold
avalues were presented as mean ± standard deviation
Table 3 Difference in values of predictors between recurrence
and no recurrence groups
recurrence no recurrence p-value*
SUVmax in FDG-PET
pre-Tx SUVmax 7.32 ± 5.47a 4.03 ± 2.32 0.10
post-Tx SUVmax 4.47 ± 2.94 2.86 ± 1.50 0.03
ΔSUVmax 2.85 ± 4.65 1.17 ± 1.73 0.29
ratio of SUVmax 0.83 ± 0.42 0.75 ± 0.34 0.56
tumor size
pre-Tx tumor size 82.40 ± 39.04 83.60 ± 34.56 0.93
post-Tx tumor size 81.30 ± 36.68 81.74 ± 36.41 0.97
Δtumor size 1.10 ± 9.36 1.85 ± 9.60 0.83
ratio of tumor size 0.89 ± 0.35 0.97 ± 0.15 0.37
*Significant p-value was bold
aValues were presented as mean ± standard deviation
Table 4 Evaluation of the predictors for recurrence after CIRT
with ROC curve
AUC (95 % CIa) p-value
SUVmax in FDG-PET
pre-Tx SUVmax 0.65 (0.43–0.88) 0.16
post-Tx SUVmax 0.66 (0.44–0.88) 0.14
ΔSUVmax 0.54 (0.29–0.79) 0.71
ratio of SUVmax 0.57 (0.35–0.79) 0.57
tumor size
pre-Tx tumor size 0.42 (0.20–0.64) 0.42
post-Tx tumor size 0.46 (0.25–0.67) 0.69
Δtumor size 0.54 (0.32–0.76) 0.73
ratio of tumor size 0.42 (0.20–0.64) 0.44
aCI confidential interval
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after CIRT, and therefore, future studies should exam-
ine what method(s) is best to detect, not to predict,
local recurrence in the early stage. In the current study,
all but one case of local recurrence were detected using
FDG-PET/CT; the remaining case was detected on en-
hanced MRI. The use of FDG-PET/CT is recommended
to identify cases of local recurrence after CIRT for bone
and soft-tissue tumors, and such evaluations are more
accurate when combined with enhanced MRI.
There were two limitations associated with this study.
First, the accumulation of long-term follow-up data was
still insufficient, and therefore, we could not analyze
whether PET/CT or any other modalities could predict
the overall survival after CIRT. Second, we could not
evaluate the risk factors or predictors of metastasis after
CIRT because the number of metastases was too small
to analyze. Recent reports have described the possibility
that heavy ions affect molecules related to tumor metas-
tasis and angiogenesis; and therefore, a further analysis
on the relationship between metastasis and CIRT is
required, although radiotherapies have been regarded
as a local therapy for cancer [7]. These two problems
can be resolved by the accumulation of more data and
continuous follow-up.
Conclusions
The combination of FDG-PET/CT and enhanced MRI is
sensitive for detecting local recurrence and should be
recommended for use in the follow-up of patients with
sarcoma who receive CIRT, although there are currently
no useful parameters of examinations performed before
or three months after the initiation of treatment that can
be used to accurately predict the development of local
recurrence.
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